En Español

Recombinant Therapies

Recombinant therapies for bleeding disorders (antihemophilic factors) are specialized therapies for coagulation deficiencies, including Factor VII, Factor VIII and Factor IX.

Recombinant therapies are derived from genetically adapted cell cultures, where an original cell derived is modified (reprogrammed) to produce specific proteins. These proteins are harvested for use in therapies.

For recombinant therapies, manufacturers rely on starter material from special production lines. Facilities harvest a small portion of these original therapy lines from controlled storage and allow the cells to multiply in several stages in order to produce enough proteins for manufacture into finished formulations. The manufacturing process requires massive investments in sophisticated technology to achieve.

Patients throughout the world rely on the critical therapies manufactured from specialized cell lines. The industry remains steadfast in providing safe, high-quality recombinant biological therapies that save and improve the lives of the individuals who depend on them.